New CML drug combo strategy aims for deeper remission without lifelong side effects

NCT ID NCT05143840

Ongoing Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times

Summary

This study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this approach can safely lead to very low levels of cancer cells in the blood. About 100 participants will take asciminib daily and be monitored closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT CML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT CML CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE LEUKEMIA, MYELOID LEUKEMIA,MYELOID, CHRONIC

Contacts and locations

Locations

Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Georgia Cancer Center at Augusta University

Augusta, Georgia, 30912, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
Winship Cancer Institute Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.